secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2024-05-28T23:59:59+00:00
Accession:  0001559053-24-000019
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena licenses PRX019 to BMS for $80M upfront; milestones up to $617.5M
--------------------------------------------------------------------------

- Upfront payment of $80 million from BMS; eligible for additional development and regulatory milestones up to $242.5M.
- Sales milestones up to $375M upon achieving certain annual net sales thresholds.
- Tiered royalties on worldwide net sales ranging from high single-digit to high teen percentages.
- Prothena obligated to run Phase 1 for PRX019; BMS may elect to take over the trial.
- Research term under Master Collaboration Agreement expired on May 24, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905324000019/0001559053-24-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905324000019/prta-20240524.htm
  HTML page:      https://secwatch.observer/filing/0001559053-24-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer